Alterity Therapeutics Stock Today
| ATHE Stock | USD 4.57 1.66 57.04% |
Performance20 of 100
| Odds Of DistressLess than 8
|
Alterity Therapeutics is trading at 4.57 as of the 31st of January 2025, a 57.04 percent increase since the beginning of the trading day. The stock's lowest day price was 4.07. Alterity Therapeutics has only a 8 % chance of going through financial distress over the next few years and had a solid performance during the last 90 days. The performance scores are derived for the period starting the 3rd of September 2024 and ending today, the 31st of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of September 2002 | Category Healthcare | Classification Health Care |
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimers disease, Huntington disease, Parkinsons disease, and other neurological disorders in Australia. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. The company has 8.74 M outstanding shares of which 84.25 K shares are presently shorted by private and institutional investors with about 1.04 trading days to cover. More on Alterity Therapeutics
Moving against Alterity Stock
Alterity Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CoFounder Chairman | Geoffrey BSc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAlterity Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alterity Therapeutics' financial leverage. It provides some insight into what part of Alterity Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alterity Therapeutics (ATHE) is traded on NASDAQ Exchange in USA. It is located in 350 Collins Street, Melbourne, VIC, Australia, 3000 and employs 10 people. Alterity Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 41.21 M. Alterity Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 8.74 M outstanding shares of which 84.25 K shares are presently shorted by private and institutional investors with about 1.04 trading days to cover.
Alterity Therapeutics currently holds about 34.81 M in cash with (12.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87.
Check Alterity Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Alterity Therapeutics is $41.21 Million. Almost 98.63 percent of Alterity Therapeutics outstanding shares are held by general public with 1.37 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Alterity Ownership Details
Alterity Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Coppell Advisory Solutions Llc | 2024-09-30 | 5.0 | |
| Xtx Topco Ltd | 2024-06-30 | 0.0 | |
| Corecap Advisors, Llc | 2024-09-30 | 0.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 44.5 K | |
| Hb Wealth Management, Llc | 2024-09-30 | 23.8 K | |
| Susquehanna International Group, Llp | 2024-09-30 | 13.9 K | |
| Ubs Group Ag | 2024-09-30 | 12.7 K | |
| Citadel Advisors Llc | 2024-09-30 | 11.5 K | |
| Twin Lakes Capital Management, Llc | 2024-09-30 | 5.9 K | |
| Providence Capital Advisors, Llc | 2024-09-30 | 200 | |
| Advisor Group Holdings, Inc. | 2024-09-30 | 81.0 |
Alterity Therapeutics Historical Income Statement
Alterity Stock Against Markets
Alterity Therapeutics Corporate Management
| Robert Cherny | Head Research | Profile | |
| BBus CA | Company Sec | Profile | |
| BSc BSc | CoFounder Chairman | Profile | |
| Kathryn Andrews | Chief Officer | Profile | |
| Steven Targum | Chief Advisor | Profile | |
| CPA BCom | Chief Officer | Profile | |
| Steven MD | Chief Advisor | Profile |
Already Invested in Alterity Therapeutics?
The danger of trading Alterity Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alterity Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alterity Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alterity Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.10) | Revenue Per Share | Quarterly Revenue Growth 0.384 | Return On Assets | Return On Equity |
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.